Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 3, 2014, Pages 492-499

  Kilić, Ana ^a,c   Huang, Cathy X ^a   Rajapurohitam, Venkatesh ^a   Madwed, Jeffrey B ^b,d   Karmazyn, Morris ^a  

^a WESTERN UNIVERSITY   (Canada)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; N [4 ( 1 ACETYLPIPERIDIN 4 YL) 3 TRIFLUOROMETHYLBENZOYL]GUANIDINE; PROTEIN INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN 1; UNCLASSIFIED DRUG; GROWTH FACTOR-ACTIVATABLE NA-H EXCHANGER NHE-1; ISOPROTEIN; PIPERIDINE DERIVATIVE; SODIUM PROTON EXCHANGE PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; HEART FAILURE; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC PRESSURE; HEART MUSCLE REPERFUSION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; IN VITRO STUDY; IN VIVO STUDY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; NEWBORN; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMEGALY; CELL CULTURE; CHEMISTRY; CORONARY BLOOD VESSEL; DRUG EFFECTS; HEART MUSCLE CELL; LIGATION; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; CORONARY VESSELS; HEART FAILURE; LIGATION; MYOCYTES, CARDIAC; PIPERIDINES; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-HYDROGEN ANTIPORTER; TIME FACTORS;

EID: 84908193718     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.217091     Document Type: Article

References (33)

1. Baartscheer A, Schumacher CA, van Borren MM, Belterman CN, Coronel R, and Fiolet JW (2003) Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57:1015-1024.
2. Chahine M, Bkaily G, Nader M, Al-Khoury J, Jacques D, Beier N, and Scholz W (2005) NHE-1-dependent intracellular sodium overload in hypertrophic hereditary cardiomyopathy: prevention by NHE-1 inhibitor. J Mol Cell Cardiol 38:571-582.
3. Chen L, Gan XT, Haist JV, Feng Q, Lu X, Chakrabarti S, and Karmazyn M (2001) Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the Na+-H+ exchange inhibitor cariporide. J Pharmacol Exp Ther 298:469-476.
4. Chen L, Chen CX, Gan XT, Beier N, Scholz W, and Karmazyn M (2004) Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition. Am J Physiol Heart Circ Physiol 286:H381-H387.
5. Cingolani HE, Alvarez BV, Ennis IL, and Camilión de Hurtado MC (1998) Stretch-induced alkalinization of feline papillary muscle: an autocrine-paracrine system. Circ Res 83:775-780.
6. Cingolani HE, Ennis IL, Aiello EA, and Pérez NG (2011) Role of autocrine/paracrine mechanisms in response to myocardial strain. Pflugers Arch 462:29-38.
7. Engelhardt S, Hein L, Keller U, Klämbt K, and Lohse MJ (2002) Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in β(1)-adrenergic receptor transgenic mice. Circ Res 90:814-819.
8. Ennis IL, Escudero EM, Console GM, Camihort G, Dumm CG, Seidler RW, Camilión de Hurtado MC, and Cingolani HE (2003) Regression of isoproterenol-induced cardiac hypertrophy by Na 1 /H 1 exchanger inhibition. Hypertension 41:1324-1329.
9. Ennis IL, Garciarena CD, Escudero EM, Pérez NG, Dulce RA, Camilión de Hurtado MC, and Cingolani HE (2007) Normalization of the calcineurin pathway underlies the regression of hypertensive hypertrophy induced by Na+/H+ exchanger-1(NHE-1) inhibition. Can J Physiol Pharmacol 85:301-310.
10. Frey N and Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45-79.
11. Gan XT, Chakrabarti S, and Karmazyn M (2003) Increased endothelin-1 and endothelin receptor expression in myocytes of ischemic and reperfused rat hearts and ventricular myocytes exposed to ischemic conditions and its inhibition by nitric oxide generation. Can J Physiol Pharmacol 81:105-113.
12. Guo J, Gan XT, Haist JV, Rajapurohitam V, Zeidan A, Faruq NS, and Karmazyn M (2011) Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation. Circ Heart Fail 4:79-88.
13. Hausenloy DJ and Yellon DM (2010) The second window of preconditioning (SWOP) where are we now? Cardiovasc Drugs Ther 24:235-254.
14. Huber JD, Bentzien J, Boyer SJ, Burke J, De Lombaert S, Eickmeier C, Guo X, Haist JV, Hickey ER, and Kaplita P, et al. (2012) Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat. J Med Chem 55:7114-7140.
15. Javadov S, Baetz D, Rajapurohitam V, Zeidan A, Kirshenbaum LA, and Karmazyn M (2006) Antihypertrophic effect of Na+/H+ exchanger isoform 1 inhibition is mediated by reduced mitogen-activated protein kinase activation secondary to improved mitochondrial integrity and decreased generation of mitochondrial-derived reactive oxygen species. J Pharmacol Exp Ther 317:1036-1043.
16. Karmazyn M (2013) NHE-1: still a viable therapeutic target. J Mol Cell Cardiol 61:77-82.
17. Karmazyn M, Gan XT, Humphreys RA, Yoshida H, and Kusumoto K (1999) The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease. Circ Res 85:777-786.
18. Karmazyn M, Kilić A, and Javadov S (2008) The role of NHE-1 in myocardial hypertrophy and remodelling. J Mol Cell Cardiol 44:647-653.
19. Kilić A, Rajapurohitam V, Sandberg SM, Zeidan A, Hunter JC, Said Faruq N, Lee CY, Burnett JC, Jr, and Karmazyn M (2010) A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway. Cardiovasc Res 88:434-442.
20. Kilić A, Velic A, De Windt LJ, Fabritz L, Voss M, Mitko D, Zwiener M, Baba HA, van Eickels M, and Schlatter E, et al. (2005) Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice. Circulation 112:2307-2317.
21. Krum H and Teerlink JR (2011) Medical therapy for chronic heart failure. Lancet 378:713-721.
22. Mraiche F, Oka T, Gan XT, Karmazyn M, and Fliegel L (2011) Activated NHE1 is required to induce early cardiac hypertrophy in mice. Basic Res Cardiol 106:603-616.
23. Nakamura TY, Iwata Y, Arai Y, Komamura K, and Wakabayashi S (2008) Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 103:891-899.
24. Orlowski J and Grinstein S (2011) Na1/H1 exchangers. Compr Physiol 1:2083-2100.
25. Ovize M, Thibault H, and Przyklenk K (2013) Myocardial conditioning: opportunities for clinical translation. Circ Res 113:439-450.
26. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, and Ford ES, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2011) Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123:e18-e209.
27. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, and Olson EN, et al. (2001) Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98:3328-3333.
28. Touret N, Tanneur V, Godart H, Seidler R, Taki N, Bürger E, Dämmgen J, and Counillon L (2003) Characterization of sabiporide, a new specific NHE-1 inhibitor exhibiting slow dissociation kinetics and cardioprotective effects. Eur J Pharmacol 459:151-158.
29. Vega RB, Rothermel BA, Weinheimer CJ, Kovacs A, Naseem RH, Bassel-Duby R, Williams RS, and Olson EN (2003) Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci USA 100:669-674.
30. Wallert MA and Fröhlich O (1992) Alpha 1-adrenergic stimulation of Na-H exchange in cardiac myocytes. Am J Physiol 263:C1096-C1102.
31. Xue J, Mraiche F, Zhou D, Karmazyn M, Oka T, Fliegel L, and Haddad GG (2010) Elevated myocardial Na+/H+ exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy. Physiol Genomics 42 :374-383.
32. Youn TJ, Piao H, Kwon JS, Choi SY, Kim HS, Park DG, Kim DW, Kim YG, and Cho MC (2002) Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction. Eur J Heart Fail 4:713-718.
33. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, Tebbe U, Schröder R, and Tiemann R, et al.; ESCAMI Investigators (2001) The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 38:1644-1650.